Introduction
The p53 protein is probably the best known of all tumor sup pressors. In about half of all human cancers, p53 is either lost or mutated in a way that compromises its function. It is well estab lished that loss or inhibition of p53 prevents cellular senescence and apoptosis. And more recently, it has become clear that in situations where p53 function is compromised, other key pro cesses that impact tumor progression, such as cell migration and invasion, are altered. In various cancers, mutations have been found throughout Tp53, the gene that encodes p53. Many of these mutations give rise to mutant p53 proteins that are highly expressed. Recent data indicate that some of the most common mutant p53 proteins have, in addition to losing transcriptional function, acquired a gain of function: these mutants drive tumor cell migration and metastasis that is in part a result of their abil ity to interfere with another p53 family member, p63.
Loss of p53 is associated with an EMT-like phenotype
Normally, p53 levels are suppressed by the activity of the E3 ubiq uitin ligase MDM2 (mouse double minute 2; Haupt et al., 1997; Kubbutat et al., 1997) . However, cellular stresses, such as DNA damage or oncogene activation, can alleviate this suppres sion, leading to p53 stabilization. Thus, in tumors where p53 expression is lost, the consequent inability of cells to engage apoptosis or senescence after stressful insults contributes to tumor formation. However, in order to metastasize, tumor cells must disseminate from the primary tumor, invade the stroma to reach blood or lymph vessels, and then extravasate to colonize other tissues. In addition to affecting apoptosis and cellular senescence, p53 loss has recently been shown to influence cell motility in a way that can contribute to a tumor's invasive and metastatic potential.
The Slug/Snail and Twist families of transcription factors are master regulators of key events in embryonic development, in particular the epithelial-mesenchymal transition (EMT; Shiota et al., 2008) . These transcriptional programs are char acterized by the loosening of cell-cell junctions and the acquisi tion of a more motile mesenchymal phenotype. More recently, Slug/Snail and Twist proteins have been shown to down regulate molecules involved in stabilizing cell-cell junctions (such as Ecadherin) , and to upregulate components of the migratory machinery in order to become invasive (Bolós et al., 2003; Shih et al., 2005) . Clearly, there is an important inter action between these master regulators of EMT and p53 ( Fig. 1 ; Wang et al., 2009b) . It is thought that in order to drive EMT, Twist opposes p53 function, indicating that p53 maintains a transcriptional program to prevent EMT and that loss of this suppression may contribute to the induction of an EMTlike phenotype in p53null tumors (Shiota et al., 2008; Smit and Peeper, 2008) . The reciprocal relationship between p53 and the execution of an EMTlike program is further exemplified by recent observations that expression of p53 can promote MDM2mediated degradation of Slug to enhance Ecadherin expression (Wang et al., 2009b) . Consistent with the paradigm that carcinogenesis carries many characteristics of EMT, loss of Ecadherin is frequently observed in cancer, and this has been shown to be capable of driving metastasis in animal models (Derksen et al., 2006) . In p53 +/ mice, most of the chemically induced papillomas with undetectable p53 expression display Ecadherin loss from the cell membrane, whereas papillomas
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p53 and its mutants in tumor cell migration and invasion cell motility through the stroma. Expression of fibronectin and collagens, ECM proteins that are intrinsically associated with the acquisition and implementation of an elongated mesenchy mal migratory phenotype, are strongly increased after p53 loss (Guo and Zheng, 2004) , potentially enhancing the interaction between cell and ECM to allow for cell motility.
It is clear that both the synthesis/deposition of ECM pro teins and their degradation by extracellular proteases are impor tant during the invasive process. Two recent studies have revealed a role for p53 in suppressing invadopodia that can trigger deg radation of components of the ECM and basal membrane to allow cells to access the stroma. In one of these studies, the actinbinding protein Caldesmon was identified as a transcrip tional target of p53. Caldesmon has been shown to inhibit po dosome formation after oncogenic transformation by activated forms of Src (Mukhopadhyay et al., 2009) . Additionally, p53 has been shown to regulate the microRNA (miRNA) 143 that might target various components of the invadopodia formation machinery and therefore inhibit podosome formation ( Fig. 1 ; Quintavalle et al., 2010) .
Loss of p53 activates Rho GTPases and their associated signaling pathways
Although p53's ability to control expression of cytoskeletal and ECM proteins is undoubtedly important, it is also evident that signaling pathways modulating cell migration and the chemo tactic responses are influenced by p53. Most signals leading to altered cell migration and invasion converge on the Rho family of small GTPases. Members of this family, including Rac, cdc42, and Rho, control actin dynamics and are integral to cytoskeletal that retain wildtype p53 expression display normal Ecadherin expression (Cano et al., 1996) . Increased Slug expression can also be identified in many p53null tumors, and this correlates with loss of Ecadherin (Shih et al., 2005; Castro Alves et al., 2007) , which indicates that p53 loss can activate a more mesen chymal phenotype in human cancer. However, as not all tumors with p53 loss can be regarded as having undergone EMT, rela tively straightforward relationships between p53 expression and EMT regulators that have been identified in ex vivo and animal cancer models may not be considered as axioms with respect to the human disease. After their dissemination from tumors, metastatic cells acquire the capacity to actively migrate and invade through the stroma. Indeed, several studies have shown that deletion of p53 can change the morphology and polarity of fibroblasts, and that this allows them to migrate faster in scratchwound assays and through 3D matrices, such as Matrigel (Alexandrova et al., 2000; Gadéa et al., 2002; Guo et al., 2003; Guo and Zheng, 2004; Gadea et al., 2007 . Moreover, studies linking loss of p53 to increased cell motility are not restricted to fibroblasts; similar observations have been made in other cell types including kera tinocytes (Lefort et al., 2007) , epithelial cancer lines (HCT116 and H1299; Sablina et al., 2003; Xia and Land, 2007) , and neu rons where increased growth cone motility has been associated with compromised p53 function (Qin et al., 2009) . It has been known for some time that p53regulated genes include compo nents of the adhesive machinery that are known to contribute to Sablina et al., 2003; Guo and Zheng, 2004; Roger et al., 2006; Gadea et al., 2007; Lefort et al., 2007; Xia and Land, 2007; Qin et al., 2009) .
RhoA acts through its main effector Rhoassociated coiledcoil containing protein kinase (ROCK) to promote con tractility, favoring rounded amoeboid migration as opposed to the elongated mode favored by Rac (Sahai and Marshall, 2003) . It is not clear how amoeboid migration fits into an EMT para digm for tumor progression, but it certainly drives very rapid translocation of tumor cells through Matrigel and collagen gels, and intravital imaging indicates that this is how many tumor cells migrate in vivo (Pinner and Sahai, 2008) . There is good consensus in the literature that loss of p53 leads to increased levels of GTPbound, active RhoA and activated ROCK, although the molecular details of how this occurs and conclu sions as to whether this represents the sole route from p53 loss to altered migration varies somewhat between studies (Guo and Zheng, 2004; Gadea et al., 2007; Lefort et al., 2007; Qin et al., 2009) . Indeed, Gadéa and coworkers have reported that the morphological changes occurring in p53 / fibroblasts can be caused by activation of cdc42 (Gadéa et al., 2002) and/or RhoA/ROCK signaling (Gadea et al., 2007) . However, given that the enhanced amoeboid migration of p53null fibroblasts can be opposed by pharmacological inhibition of ROCK changes accompanying tumor cell migration and invasion (Bishop and Hall, 2000; Heasman and Ridley, 2008) . The up stream control of RhoGTPase activity is primarily mediated by molecules that influence their GTP loading, including RhoGAPs (Rho GTPaseactivating proteins), which turn them off by in creasing GTP hydrolysis, and RhoGEFs (Rho guanine nucleo tide exchange factors) that activate them (SanzMoreno and Marshall, 2009) .
The balance between the activities of Rac and Rho has been wellestablished to influence the way in which tumor cells migrate (Sahai and Marshall, 2003; SanzMoreno and Marshall, 2009) . When Rac predominates, migration proceeds with the elongated morphology characteristic of tumor cells that have assumed a mesenchymal phenotype. Thus, given p53's ability to suppress Slug and its attendant EMTlike program, it might be expected that p53deficient cells would have increased levels of active Rac. Possible links between p53 and Rac can be garnered by considering findings that the PTEN gene, a lipid phosphatase that reduces levels of PIP3, leading to inhibition of PIP3dependent GEFs for Rac and cdc42, can be transacti vated by p53 (Stambolic et al., 2001 ). However, although Rac and cdc42 activation was initially reported in p53null cells, most subsequent studies have focused on increased activity of RhoA after loss of p53 (Table I and Selected list of genes with an involvement in EMT, cell migration, and ECM degradation that are regulated by p53. p53 status, suppression or loss of wild-type p53.
will focus on the gain of function of mutant p53 in driving tumor cell migration. Gain of function of mutant p53 in driving cell migra tion has been shown across different contexts, including cell movement on 2D surfaces, invasivetype migration through 3D matrices (such as Matrigel), and metastasis of mutant p53 cells implanted as xenografts (Dhar et al., 2008; Junk et al., 2008; Adorno et al., 2009; Muller et al., 2009) . To gain insight into how this gain of function is achieved by mutant p53, several groups have addressed the possibility that mutant p53 expression changes the transcriptional profile of cells in a p53null back ground. Interestingly, many mutant p53regulated genes are ones that would be expected to influence cell migration either directly or indirectly (Table II) . Indeed, mutant p53s can act via Slug or Twist to induce partial EMTlike transitions that are reflected in their ability to suppress Ecadherin synthesis (Wang et al., 2009b; KoganSakin et al., 2010) , or this can be me diated via suppression of the antiinvasive gene CCN5/WISP2 (Dhar et al., 2008) . Many cancer cells invade the stroma using an amoeboid migratory mode that is promoted by increased RhoA/ROCK signaling, and several studies have found compo nents of this pathway to be transcriptionally regulated by mu tant p53s. Indeed, recent studies indicate that both the guanine nucleotide dissociation inhibitor (RhoGDI; Bossi et al., 2008) and an exchange factor for RhoA (Rho GEFH1; Mizuarai et al., 2006) are upregulated by mutant p53s, and more work will be needed to determine how the combination of these changes im pacts on GTPRhoA levels and the acquisition of amoeboid type migration in cancer.
Mechanisms of mutant p53's gain of function
Overall, two main mechanisms that could underlie mutant p53's gain of function have been intensively studied by many groups. First, mutant p53 has been proposed to be a transcrip tion factor in its own right. Even though the majority of mu tations within p53 occur in the DNA binding domain, mutant p53s might still influence promoter activity via the Nterminal transactivation domain, and, as the expression of mutant p53 is often very high in many cancers, this may be sufficient to drive the expression of its own set of target genes (Weisz et al., 2004; Zalcenstein et al., 2006) . Indeed, the ability of mutant p53 to oppose apoptosis is ablated by removal of its Nterminal transactivation domain (Lin et al., 1995; Matas et al., 2001 ). However, mutant p53 is also known to operate by interfering with and/or modifying the function of other proteins. For in stance, mutant p53 can interact with Mre11 to prevent ataxia telangiectasia mutated (ATM)dependent DNA repair (Song et al., 2007; Liu et al., 2010) . Importantly, p53 is also known to impose upon the function of other transcription factors, in cluding the wellstudied p53 family members, p63 and p73, that share a homologous transactivation domain, a DNA bind ing domain, and an oligomerization domain. Indeed, both cell based assays (Di Como et al., 1999; Strano et al., 2000 Strano et al., , 2002 and knockin mice expressing mutant forms of p53 support a mechanism by which mutant p53s interact with p63 and p73, and negatively regulate their function (Lang et al., 2004; Li and (Gadea et al., 2007) , it is likely that RhoA is an important effector of p53 with regard to this type of tumor cell migration. It is not clear how p53 loss leads to ROCK activation, but recent studies have suggested two plausible mechanisms by which this might occur. In keratinocytes, the expression of ROCK is re pressed by p53 via downregulation of Notch1 (Lefort et al., 2007) . Additionally, the atypical Rho protein RhoE (or Rnd3) is a p53 target gene that opposes activation of RhoA (Ongusaha et al., 2006) . Indeed, this can be mediated via RhoE's ability both to inhibit Syx (a GEF that activates RhoA; Goh and Manser, 2010) and to activate p190RhoGAP (a key RhoA inacti vator; Wennerberg et al., 2003) . Furthermore, loss of p53 has been shown to reduce phosphorylation of p190RhoGAP on Tyr 1105 in Rastransformed cells (Xia and Land, 2007) to oppose RhoGAP activity (Fig. 1) . These observations collectively pro vide evidence for signaling mechanisms through which p53 loss can drive increased activity of the RhoA/ROCK axis to promote cell motility and invasion during tumor progression.
Mutant p53 proteins drive an aggressive cancer phenotype by gain of function
Although p53 knockout mice are highly tumor prone, these le sions do not metastasize frequently, nor do they generally dis play invasive pathology (Attardi and Jacks, 1999) . This suggests that p53 loss is not, in itself, sufficient to drive invasive migra tion in vivo. However, in many human tumors, p53 expression is not lost, but the gene acquires point mutations that disrupt the ability of the p53 protein to bind to DNA. Two p53 mutants that are commonly found in human cancer and that have been extensively used to study p53's role in cell migration are R273H (R270H in mice), which directly compromises DNA binding, and R175H (R172H in mice), which causes a global confor mational distortion of p53 (Cho et al., 1994) . These mutations inhibit p53's ability to act as a transcription factor, account ing for their reduced ability to function as tumor suppressors. Moreover, these mutant p53 proteins are often expressed at very high levels in cancer cells, and a growing body of evidence now supports additional gainoffunction roles for mutant p53s in the context of tumorigenesis, cancer invasion, and metastasis (Oren and Rotter, 2010) Indeed, introduction of mutant p53s (R172H or R270H) leads to a marked increase in the incidence of highly metastatic carcinomas in various mouse models (Liu et al., 2000; Lang et al., 2004; Olive et al., 2004; Heinlein et al., 2008; Doyle et al., 2010; Morton et al., 2010) .
Mutant p53 proteins and cell migration
Wildtype p53 can be inhibited in trans by p53 mutants under conditions of high mutant p53 expression, so it is only possible to assign bona fide gain of function to mutant p53s when they are expressed in a p53null background. Using both cellbased approaches and knockin mice, mutant p53s have been shown to acquire new functions in processes such as proliferation, resis tance to apoptosis, genomic instability, somatic cell reprogram ming, and cell migration and invasion (Li et al., 1998; Gurtner et al., 2010; Liu et al., 2010; Oren and Rotter, 2010; Sarig et al., 2010; Stambolsky et al., 2010) . Although many of these pro cesses will likely contribute to tumor aggressiveness, here we p53 and cell migration • Muller et al.
Although mutations in p63 have rarely been found, loss of p63 is seen in a range of tumor types correlating closely with the in vasiveness of these cancers (Park et al., 2000; Urist et al., 2002; Wang et al., 2002; Koga et al., 2003; Chen et al., 2004) . With regard to invasiveness, p63 loss may be restricted to the TAp63 isoform, reinforcing the view that TAp63 functions as a sup pressor of metastasis (Park et al., 2000; Chen et al., 2004) . Furthermore, p63 +/ mice can spontaneously develop solid ma lignant lesions, which primarily include squamous cell and his tiocytic sarcomas that are highly metastatic (Flores et al., 2005) . Interestingly, most tumor formation in p63 +/ mice is accompa nied by loss of the remaining p63 allele, and in tumors where this does not occur, it is primarily the Np63 isoform that re mains (Flores et al., 2005) . More recent data obtained in TAp63 specific knockout mice indicate that TAp63 is required to drive Rasdependent senescence and that its loss results in rapid p53 independent tumorigenesis, which further supports a role for TAp63 in tumor suppression (Guo et al., 2009) . At the cellular level, it is clear that siRNA knockdown of p63 increases inva sive migration of H1299 nonsmall lung cell carcinoma cells (Adorno et al., 2009; Muller et al., 2009 ). H1299 cells predomi nantly express TAp63 (Muller et al., 2009) , and expression of mutant p53 recapitulates the effects of TAp63 loss, which indi cates that mutant p53's gain of function may operate by specifi cally inhibiting the TA isoform of p63 (Adorno et al., 2009; Muller et al., 2009) . These data also further demonstrate that the TAp63 isoform functions as an inhibitor of invasion.
So how do mutant p53s inhibit p63? Physical interactions between mutant p53s and p63 that directly impair its tran scriptional functions have been described previously (Gaiddon et al., 2001; Strano et al., 2002; Li and Prives, 2007) . How ever, the relationship between mutant p53's ability to bind p63 and its capacity to functionally inhibit it to promote invasion is Prives, 2007) . For example, knockdown of either p63 or p73 is as effective as expression of a mutant p53 in increasing the colonyforming potential of fibroblasts from p53 / mice. Furthermore, knockdown of p63 or p73 does not further increase colony formation in cells expressing a mutant p53, which indi cates the likelihood that these three p53 family members may be acting on similar pathways to tumorigenesis (Lang et al., 2004) . Moreover, removal of the transactivation domain from mutant p53s does not interfere with its invasive capabilities, suggest ing that gain of function in driving invasion is predominantly mediated by inhibition of p63 and/or p73 (Adorno et al., 2009; Muller et al., 2009). p63 is an effector of mutant p53 p63 expression is driven by two alternative promoters, resulting in a fulllength TA isoform or an Nterminally truncated N form that lacks the transactivation domain. Furthermore, Np63 and TAp63 transcripts can be spliced to yield , , or  variants with alternative C termini. Not only do these isoforms and vari ants have different expression patterns according to cell type and differentiation status, they have been reported to possess different and sometimes opposing functions, which complicates the understanding of p63 function. cDNA microarray data indi cates that overexpression of Np63 or TAp63 results in largely nonoverlapping gene expression profiles, which suggests that these two p63 isoforms could have different target genes (Wu et al., 2003; Carroll et al., 2006) . However, observations that Np63 opposes TAp63 as an inducer of apoptosis suggest that it might exert inhibition over the TA isoform, nominate TAp63 as a tumor suppressor, and nominate Np63 to be a tumor pro moter (Candi et al., 2007) .
To be a suppressor of tumor growth and metastasis, one might expect p63 to be mutated or lost in human cancers. Selected list of genes/proteins that affect EMT, cell migration, invasion, and metastasis that are regulated by mutant p53 in a gain-of-function manner. p53 status, expression of mutant p53s in p53 / background.
are likely other members of the mutant p53-p63 complex that influence the way in which the two proteins associate. Adorno et al. (2009) have shown a role for TGF signaling in promot ing the ability of mutant p53 to bind to and inhibit p63. These investigators demonstrated that SMAD2 phosphorylated down stream of TGF can serve as a platform for assembly of the mutant p53-p63 complex. This pathway illustrates an important mechanism by which TGF can control invasion. However, the relationships between TGF signaling and mutant p53 are not not straightforward. Although both the R175H and R273H mutants of p53 are equally capable of inhibiting TAp63 and promoting invasion, p53R175H binds more tightly to TAp63 in coimmunoprecipitation experiments (Gaiddon et al., 2001; Strano et al., 2002; Li and Prives, 2007) . Furthermore, a Cterminally truncated mutant p53 does not drive invasion, but still interacts with TAp63, which suggests that mutant p53's inhibition of p63 is not dictated exclusively by the capacity of the two proteins to associate with one another. Moreover, there to identify genes that may regulate components of the miRNA processing complex, an RNase III endonuclease, Dicer, was identified as a possible target of TAp63 (Boominathan, 2010) . Conformation that Dicer is indeed a target gene of TAp63 was recently provided by an elegant study showing that TAp63 regu lates Dicer to prevent metastasis (Su et al., 2010) . p63null mice die soon after birth because of severe skin defects. To parallel this, the epidermisspecific knockout of Dicer leads to impaired development of hair follicles (Andl et al., 2006) . Downregulation of miRNA processing is known to occur in a range of cancers (Lu et al., 2005; Kumar et al., 2009) , and reduced levels of en zymes such as Dicer correlate with a poor prognosis (Grelier et al., 2009) . Moreover, it has recently been shown that reduced levels of Dicer can promote tumorigenesis and invasion (Kumar et al., 2009; Han et al., 2010; Lambertz et al., 2010; Martello et al., 2010; Su et al., 2010) . Furthermore, decreased Dicer levels correlate with increased activation of PKB/Akt, which suggests that it might act on the same pathway to induce inva sion as mutant p53 and p63 (Han et al., 2010) . Hopefully, future work will resolve the molecular details of the connection between p63 suppression, miRNA processing, and invasion. In particu lar, it will be interesting to determine whether components of the trafficking machinery that transport 51 integrin from re cycling endosomes to the cell surface represent key targets of p63regulated miRNAs.
Mutant p53, p63, and growth factor receptor trafficking
In addition to controlling recycling of 51 integrin, RCP can physically link the integrin to the EGF receptor (EGFR), thus mediating cotrafficking of these two important regulators of cell migration (Caswell et al., 2008) . Moreover, because this process leads to increased return of internalized EGFR1 to the plasma membrane (thus diverting it from the route to lyso somal degradation), it also enhances signaling downstream of EGFR1 (Caswell et al., 2008) . Consistent with this, mutant p53 expressing cells have enhanced levels of active PKB/Akt (Fig. 2 B ; Dong et al., 2009; Muller et al., 2009) , and the mutant p53 status of human and mouse cancers correlates with the degree of PKB/Akt activation (Muller et al., 2009; BlancoAparicio et al., 2010) . PKB/Akt is an important prosurvival kinase that more recently has been established to play a key role in pro moting cell migration during the invasive program. This indi cates the likelihood that mutant p53driven recycling conveys its signals to the cell's invasive machinery, at least in part, via PKB/Akt. Another member of the EGFR family, ErbB2, can heterodimerize with EGFR1, and is known to cooperate with mutant p53 to increase tumorigenesis in mice (Li et al., 1997) . Furthermore, in breast cancers, mutant p53 status in combina tion with high ErbB2 expression is associated with a very poor prognosis (Rahko et al., 2003) . Alternative trafficking routes for EGFR1/ErbB2 heterodimers are thought to influence EGF sig naling in cancer (Lenferink et al., 1998) , and the possibility that the 51 integrin-RCP complex recruits and controls recycling of EGFR1/ErbB2 heterodimers and other prometastatic recep tors with known connections to mutant p53, such as IGF1R and cMet, should be considered.
straightforward, and it would seem that TGF signaling is not always required for mutant p53 to function (Kalo et al., 2007; Muller et al., 2009) . It is well known that TGF signaling has many complex and opposing roles in cancer progression (Jakowlew, 2006) , and the involvement of phosphoSMAD2 in the regulation of p63 and cell migration by mutant p53 sheds some interesting light on at least some of the functions of TGF in cancer progression.
Downstream of p63 to drive invasion and metastasis
Transcriptome studies indicate that knockdown of p63 increases expression of known mediators of motility, invasion, and metas tasis (Barbieri et al., 2006; Carroll et al., 2006; Gu et al., 2008) .
To identify factors downstream of p63 that were responsible for invasion, Adorno et al. (2009) investigated genes that were co regulated by mutant p53 and TGF, and identified Sharp1 and Cyclin G2 as important targets. Suppression of either Sharp1 or Cyclin G2 mimicked mutant p53's capacity to drive cell migration, and low expression of Sharp1 and Cyclin G2 was associated with poor prognosis and recurrence in breast cancer. Collectively, these data indicate that Sharp1 and Cyclin G2 are targets of p63 in regard to its ability to suppress tumor cell migration and metastasis (Fig. 2 A; Adorno et al., 2009) . But what are the components of the cell's intracellular sig naling network and/or migratory machinery that respond to p63 inhibition to engage tumor cell migration and invasion? It is now accepted that the cell's main receptor for fibronectin, 51 integrin, is a key contributor to metastatic migration of cancer cells. Indeed, Muller et al. (2009) showed that the mutant p53 driven (and p63inhibitable) component of tumor cell migration can depend on 51 integrin function and the presence of its ligand, fibronectin (Muller et al., 2009) . The way in which inte grins are internalized into endosomal compartments and returned (or recycled) to the plasma membrane influences their function, particularly with regard to their communication with RhoGTPases and their ability to influence the recycling of other receptors such as EGFR1 or VEGFR2 ). The Rab11 effector protein Rabcoupling protein (RCP) associates with 51 integrin and plays an important role in guiding integrin transport from recycling endosomes to the plasma membrane to promote movement of tumor cells in fibronectinrich 3D micro environments (Caswell et al., 2008) . Moreover, the importance of RCP in cancer progression is further illustrated by the finding that it is frequently overexpressed in human breast cancers (Zhang et al., 2009) . It is now clear that the association of RCP with 51 integrin is inhibited by transcriptionally active TAp63. This in hibition is relieved after expression of mutant p53s, allowing RCP to bind to internalized 51 integrin and rapidly transport it to the plasma membrane, thus driving tumor cell migration and invasion (Fig. 2 B; Muller et al., 2009) .
Although RCPdependent integrin recycling is a key effector pathway downstream of p63, the transcriptional targets of p63 that regulate RCP's recruitment to 51 integrin are un known. It is interesting to speculate how this may be achieved, and there are signs that miRNAs and the machinery that pro cesses them may be involved. In a computational genomic analysis
Conclusions
By comparison with p53 loss, expression of mutant p53s is associated with more invasive and metastatic cancers, which suggests that these mutants not only lose the ability to function as tumor suppressors, but that they also gain prometastatic func tions, some of which are related to increased cell migration and invasion. In general, it seems that loss of p53 is important in the loosening of cell-cell junctions and the loss of epithelial integ rity, which would be expected to contribute to dissemination of cells from solid tumors. However, most in vivo work indicates that this event in itself is insufficient to generate invasive or metastatic tumors. Mutant p53s, however, are very potent in ducers of the metastatic phenotype. This owes, at least in part, to their ability to act via p63 to drive invasivetype migration. The contribution of TGF signaling and the trafficking of inte grins and growth factor receptors to mutant p53driven invasion suggests some interesting new candidates for antimetastatic drug development. However, many questions remain as to how the ele ments of this proinvasive program are connected to one another. In particular, we anticipate that the link between p63 and the cell's migratory and trafficking machinery will provide fertile ground for those interested in targeting the metastatic process.
